TY - JOUR
T1 - Systemic methotrexate for the treatment of psoriasis
AU - Yélamos, Oriol
AU - Puig, Lluís
PY - 2015/5/1
Y1 - 2015/5/1
N2 - © 2015 Informa UK, Ltd. In the era of biologic therapies, methotrexate (MTX), a classic immunomodulator, is still the cornerstone of systemic treatment of psoriasis. MTX has been used for many years, achieving good responses with a good safety profile. However, only a few randomized clinical trials have been performed involving MTX, and most of the current evidence comes from pivotal studies of biologic drugs. The aim of this article is to make an extensive review of the MTX mechanism of action, pharmacokinetics, efficacy, safety and tolerability, especially focusing on the future perspective of this old drug and recent advances in the field of pharmacogenetics.
AB - © 2015 Informa UK, Ltd. In the era of biologic therapies, methotrexate (MTX), a classic immunomodulator, is still the cornerstone of systemic treatment of psoriasis. MTX has been used for many years, achieving good responses with a good safety profile. However, only a few randomized clinical trials have been performed involving MTX, and most of the current evidence comes from pivotal studies of biologic drugs. The aim of this article is to make an extensive review of the MTX mechanism of action, pharmacokinetics, efficacy, safety and tolerability, especially focusing on the future perspective of this old drug and recent advances in the field of pharmacogenetics.
KW - Adenosine
KW - Dihydrofolate reductase inhibitor
KW - Folic acid
KW - Methotrexate
KW - Methotrexate polyglutamates
KW - Pharmacogenetics
KW - Psoriasis
UR - https://www.scopus.com/pages/publications/84928172823
U2 - 10.1586/1744666X.2015.1026894
DO - 10.1586/1744666X.2015.1026894
M3 - Article
SN - 1744-666X
VL - 11
SP - 553
EP - 563
JO - Expert Review of Clinical Immunology
JF - Expert Review of Clinical Immunology
IS - 5
ER -